• Ocular Therapeutix recently announced that it will present additional data and analyses from its Phase 3 SOL-1 superiority trial of AXPAXLI for wet age-related macular degeneration at multiple scientific conferences in April 2026, highlighting durability, efficacy, and safety outcomes.
• These upcoming scientific presentations are set to put AXPAXLI’s clinical profile under closer scrutiny from physicians and researchers, potentially sharpening how the therapy is perceived within the competitive retinal disease landscape.
• Against this backdrop, we’ll examine how the upcoming AXPAXLI Phase 3 SOL-1 data presentations could reshape Ocular Therapeutix’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix today, you need to believe AXPAXLI can clear late stage clinical and regulatory hurdles in wet AMD and eventually support a viable commercial business, despite ongoing losses and shareholder dilution. The upcoming SOL-1 data presentations look important for shaping physician perception, but they do not by themselves resolve the bigger near term catalyst of an eventual NDA decision, or the key risk that any setback in SOL-1 or SOL-R would hit the story hard.

Among recent developments, the company’s update that SOL-1 topline data are expected in Q1 2026 is most relevant here, because the April 2026 conference presentations will effectively be the first broad, detailed look at that dataset for the clinical community. How clinicians react to durability, safety and superiority claims at these meetings could influence how credible AXPAXLI looks as the centerpiece of Ocular’s future, especially with the parallel SOL-R trial still progressing.

Yet investors should also be aware that if payer pressure intensifies and premium pricing is harder to achieve, then...

Ocular Therapeutix's narrative projects $287.1 million revenue and $57.1 million earnings by 2029.

Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 206% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to reach about US$252 million and earnings of roughly US$58 million by 2028, so if you are weighing that bullish view against new SOL-1 data and the risk of continued dilution, it is worth remembering that opinions differ widely and this latest news could ultimately shift both the upside story and the concerns around...

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.